Introduction

In early June, Canada became the first G7 nation to approve generic versions of the weight‑loss drug semaglutide, the active ingredient in Ozempic and Wegovy. The move means the drugs will now be available in Canadian pharmacies at less than a third of the current price, a shift that could reshape access for patients both inside Canada and across the Atlantic.

Body

The Canadian approval was a response to mounting pressure over high prices that have left many Canadian patients, like 69‑year‑old teacher Elizabeth Doran, turning to tourism and discount cards to afford treatment. Doran, who has previously nearly reached diabetic status, now can maintain her weight loss and health at a fraction of the cost. Likewise, Esther Linetsky, a similarly priced patient, has been able to resume therapy without rationing free samples.

Another key factor in Canada’s decision was a missed patent renewal by Novo Nordisk. The company’s main Ozempic patent, had it been renewed, could have extended exclusivity until 2028. The lapse opened the door for two generics from Dr Reddy’s and Apotex, which will hit Canadian shelves by the beginning of June.

In the United States, U.S. and European federal regulators allow companies to extend patents for several years, which keeps the drug on the market at high prices. The patent for semaglutide is not expected to expire until 2032, keeping the US market locked out of low‑cost medicines for the foreseeable future. Appeals for a patent reform push are facing stiff resistance from the pharmaceutical lobby.

Both Canadian and U.S. patients have expressed frustration. In Canada, the generics’ arrival has already forced Novo Nordisk to lower pricing on brand‑name drugs. In the U.S., the high prices have effectively limited GLP‑1 drugs to wealthier patients, leaving many who desperately need them without access. The Center for Medicare & Medicaid Innovation reports that less than 10% of eligible U.S. patients receive these treatments.

Despite the generous pricing throughout Canada, the generics’ availability in the U.S. remains uncertain. While Apotex’s product has gained tentative FDA approval, it cannot yet be sold in the U.S. market. Nevertheless, experts warn that Americans have already been seeking cheaper options across the border, mirroring a 2019 “caravan” that traveled to purchase insulin at lower prices.

Conclusion

The approval of generic semaglutide in Canada represents a significant step toward making vital weight‑loss medications more affordable. While the American patent landscape may still delay similar access, the Canadian experience signals that policy changes and competitive pressures can produce real savings for patients. As global demand for GLP‑1 drugs rises, the hope is that a similar model can emerge elsewhere, improving health outcomes and supporting preventative care worldwide.